The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma

• Published in: The European respiratory journal Vol. 22; no. 3; pp. 470 - 477
• Main Authors: Abraham, B, Anto, JM, Barreiro, E, Bel, EHD, Bonsignore, G, Bousquet, J, Castellsague, J, Chanez, P, Cibella, F, Cuttitta, G, Dahlen, B, Dahlen, SE, Drews, N, Djukanovic, R, Fabbri, LM, Folkerts, G, Gaga, M, Gratziou, C, Guerrera, G, Holgate, ST, Howarth, PH, Johnston, SL, Kanniess, F, Kips, JC, Kerstjens, HAM, Kumlin, M, Magnussen, H, Nijkamp, FP, Papageorgiou, N, Papi, A, Postma, DS, Pauwels, RA, Rabe, KF, Richter, K, Roldaan, AC, Romagnoli, M, Roquet, A, Sanjuas, C, Siafakas, NM, Timens, W, Tzanakis, N, Vachier, I, Vignola, AM, Watson, L, Yourgioti, G
• Format: Journal Article
• Language: English
• Published: England 01.09.2003
• Subjects: Administration, Inhalation; Adult; Anti-Asthmatic Agents - administration & dosage; Anti-Asthmatic Agents - therapeutic use; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - therapeutic use; Asthma - diagnosis; Asthma - drug therapy; Asthma - epidemiology; Asthma - physiopathology; Case-Control Studies; Chronic Disease; Cohort Studies; Cross-Sectional Studies; Europe - epidemiology; Female; Humans; Male; Medicin och hälsovetenskap; Respiratory Function Tests; Europe
• ISSN: 0903-1936
• DOI: 10.1183/09031936.03.00261903

Since severe asthma is a poorly understood, major health problem, 12 clinical specialist centres in nine European countries formed a European Network For Understanding Mechanisms Of Severe Asthma (ENFUMOSA). In a cross-sectional observational study, a total of 163 subjects with severe asthma were compared with 158 subjects whose asthma was controlled by low doses of inhaled corticosteroids (median dose of beclomethasone equivalents 666 microg). Despite being treated with higher doses of inhaled corticosteroids (median dose 1773 microg) and for a third of the severe asthmatics also being treated with regular, oral-steroid therapy (median daily dose 19 mg), the subjects with severe asthma met the inclusion criteria. The criteria required subjects to have undergone at least one asthma exacerbation in the past year requiring oral steroid treatment. Females dominated the severe asthma group (female/male ratio 4.4:1 versus 1.6:1 in the controlled asthmatics), and compared with controlled asthmatics, they had a predominantly neutrophilic inflammation (sputum neutrophils, 36 versus 28%) and evidence of ongoing mediator release but less atopy. From these findings and other physiological and clinical data reported in this paper, it is suggested that severe asthma might be a different form of asthma rather than an increase in asthma symptoms. The findings prompt for longitudinal studies and interventions to define the mechanisms in severe asthma.